Stock Track | Valneva SE Soars 7.55% Intraday on Positive Lyme Disease Vaccine Data

Stock Track11-27

Valneva SE (VALN) surged 7.55% during intraday trading on Wednesday, driven by positive final data from a mid-stage study of its Lyme disease vaccine candidate, VLA15, developed in collaboration with Pfizer.

The study showed that antibody levels remained well above baseline across all six Lyme disease serotypes and all age groups, six months after participants received the third yearly booster dose. The safety profile also remained favorable, with no concerns identified by the independent Data Monitoring Committee.

Analysts noted that VLA15 is the furthest-advanced Lyme disease vaccine in development, and the data increases confidence in the success of the upcoming late-stage trial, expected in the first half of 2026. This development positions Valneva as a key player in addressing the unmet need for a human Lyme disease vaccine.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment